Qiagen (NYSE:QGEN) Sets New 52-Week Low – Time to Sell?

Qiagen N.V. (NYSE:QGEN) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $38.89 and last traded at $38.9710, with a volume of 195374 shares traded. The stock had previously closed at $39.71.

Analysts Set New Price Targets

QGEN has been the topic of several recent research reports. Robert W. Baird set a $53.00 price target on Qiagen in a report on Friday, February 6th. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Deutsche Bank Aktiengesellschaft upgraded shares of Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research note on Friday, March 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Finally, Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Friday, February 6th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $55.20.

Qiagen Stock Down 1.3%

The company has a current ratio of 3.90, a quick ratio of 3.31 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $8.08 billion, a P/E ratio of 19.41, a PEG ratio of 1.98 and a beta of 0.70. The firm’s 50 day moving average price is $47.87 and its two-hundred day moving average price is $48.28.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The firm had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The company’s revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the company earned $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. Equities research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current year.

Hedge Funds Weigh In On Qiagen

Several large investors have recently modified their holdings of the business. United Services Automobile Association acquired a new position in Qiagen during the 1st quarter worth about $239,000. Cetera Investment Advisers lifted its stake in shares of Qiagen by 23.9% in the 2nd quarter. Cetera Investment Advisers now owns 17,239 shares of the company’s stock valued at $827,000 after purchasing an additional 3,322 shares during the period. JPMorgan Chase & Co. grew its stake in Qiagen by 117.0% during the second quarter. JPMorgan Chase & Co. now owns 1,252,948 shares of the company’s stock worth $60,217,000 after purchasing an additional 675,498 shares during the period. MAI Capital Management increased its holdings in Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after purchasing an additional 889 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Qiagen by 2.7% in the second quarter. Rhumbline Advisers now owns 199,503 shares of the company’s stock valued at $9,588,000 after buying an additional 5,200 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.